Literature DB >> 2517294

High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization.

G E Hofmann1, J P Toner, S J Muasher, G S Jones.   

Abstract

Follicle-stimulating hormone (FSH) was used in high doses (6 ampoules/day:6FSH) for ovarian hyperstimulation for in vitro fertilization in women with a previous poor response to stimulation with the equivalent of "4FSH." Luteinizing hormone levels did not differ between stimulations, but both FSH and estradiol levels were higher in the 6FSH compared to the 4FSH cycle. There were fewer cancellations in the 6FSH cycle, but similar numbers of preovulatory oocytes were retrieved, fertilized, and transferred. The pregnancy rates per attempt and retrieval were higher in the 6FSH cycle. We conclude that raising and maintaining FSH levels during stimulation in low responders reduced cancellations and may improve in vitro fertilization outcome.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2517294     DOI: 10.1007/bf01139183

Source DB:  PubMed          Journal:  J In Vitro Fert Embryo Transf        ISSN: 0740-7769


  14 in total

1.  Gonadotrophin excretion in fertile women: effect of age and the onset of the menopausal transition.

Authors:  M G Metcalf; J H Livesey
Journal:  J Endocrinol       Date:  1985-06       Impact factor: 4.286

2.  Use of purified gonadotrophins for ovarian stimulation in IVF.

Authors:  G S Jones
Journal:  Clin Obstet Gynaecol       Date:  1985-12

3.  An alternate approach to controlled ovarian hyperstimulation in "poor responders": pretreatment with a gonadotropin-releasing hormone analog.

Authors:  P Serafini; B Stone; J Kerin; J Batzofin; P Quinn; R P Marrs
Journal:  Fertil Steril       Date:  1988-01       Impact factor: 7.329

4.  Update on in vitro fertilization.

Authors:  G S Jones
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

5.  The perimenopausal patient in in vitro fertilization: the use of gonadotropin-releasing hormone.

Authors:  G S Jones; S J Muasher; Z Rosenwaks; A A Acosta; H C Liu
Journal:  Fertil Steril       Date:  1986-11       Impact factor: 7.329

6.  The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome.

Authors:  S J Muasher; S Oehninger; S Simonetti; J Matta; L M Ellis; H C Liu; G S Jones; Z Rosenwaks
Journal:  Fertil Steril       Date:  1988-08       Impact factor: 7.329

7.  Three years of in vitro fertilization at Norfolk.

Authors:  H W Jones; A A Acosta; M C Andrews; J E Garcia; G S Jones; J Mayer; J S McDowell; Z Rosenwaks; B A Sandow; L L Veeck
Journal:  Fertil Steril       Date:  1984-12       Impact factor: 7.329

8.  The combination of follicle-stimulating hormone and human menopausal gonadotropin for the induction of multiple follicular maturation for in vitro fertilization.

Authors:  S J Muasher; J E Garcia; Z Rosenwaks
Journal:  Fertil Steril       Date:  1985-07       Impact factor: 7.329

9.  Human menopausal gonadotropin/human chorionic gonadotropin follicular maturation for oocyte aspiration: phase II, 1981.

Authors:  J E Garcia; G S Jones; A A Acosta; G Wright
Journal:  Fertil Steril       Date:  1983-02       Impact factor: 7.329

10.  Maturation and fertilization of morphologically immature human oocytes in a program of in vitro fertilization.

Authors:  L L Veeck; J W Wortham; J Witmyer; B A Sandow; A A Acosta; J E Garcia; G S Jones; H W Jones
Journal:  Fertil Steril       Date:  1983-05       Impact factor: 7.329

View more
  11 in total

Review 1.  Treatment of low responders.

Authors:  S J Muasher
Journal:  J Assist Reprod Genet       Date:  1993-02       Impact factor: 3.412

2.  Modified natural cycle using GnRH antagonist can be an optional treatment in poor responders undergoing IVF.

Authors:  Shai E Elizur; Dilek Aslan; Adrian Shulman; Boaz Weisz; David Bider; Jehoshua Dor
Journal:  J Assist Reprod Genet       Date:  2005-02       Impact factor: 3.412

3.  The potential use of maturation in vitro of human oocytes in low responder patients.

Authors:  A Requena; F Neuspiller; A C Cobo; M Aragonés; J Remohí; C Simón; A Pellicer
Journal:  J Assist Reprod Genet       Date:  2000-05       Impact factor: 3.412

4.  Does pretreatment with progestogen or oral contraceptive pills in low responders followed by the GnRHa flare protocol improve the outcome of IVF-ET?

Authors:  E al-Mizyen; L Sabatini; A M Lower; C M Wilson; T al-Shawaf; J G Grudzinskas
Journal:  J Assist Reprod Genet       Date:  2000-03       Impact factor: 3.412

Review 5.  Evaluation and treatment of low responders in assisted reproductive technology: a challenge to meet.

Authors:  S J Fasouliotis; A Simon; N Laufer
Journal:  J Assist Reprod Genet       Date:  2000-08       Impact factor: 3.412

6.  The clinical analysis of poor ovarian response in in-vitro-fertilization embryo-transfer among Chinese couples.

Authors:  X M Zhen; J Qiao; R Li; L N Wang; P Liu
Journal:  J Assist Reprod Genet       Date:  2008-01-18       Impact factor: 3.412

Review 7.  Different ovarian stimulation protocols for women with diminished ovarian reserve.

Authors:  D Loutradis; P Drakakis; E Vomvolaki; A Antsaklis
Journal:  J Assist Reprod Genet       Date:  2007-11-22       Impact factor: 3.412

8.  Decreased fertility in poor responder women is not related to oocyte morphological status.

Authors:  Marcílio Nichi; Rita de Cassia Sávio Figueira; Daniela Paes de Almeida Ferreira Braga; Amanda Souza Setti; Assumpto Iaconelli; Edson Borges
Journal:  Arch Med Sci       Date:  2011-05-17       Impact factor: 3.318

9.  FSH dose is negatively correlated with number of oocytes retrieved: analysis of a data set with ~650,000 ART cycles that previously identified an inverse relationship between FSH dose and live birth rate.

Authors:  Zaramasina L Clark; Mili Thakur; Richard E Leach; James J Ireland
Journal:  J Assist Reprod Genet       Date:  2021-04-08       Impact factor: 3.357

Review 10.  Management of poor responders in IVF: is there anything new?

Authors:  Filippo Ubaldi; Alberto Vaiarelli; Rosario D'Anna; Laura Rienzi
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.